The Lancet HIV Journal

Overview
Identity
View All

publication venue for

Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies. 11:e106-e116. 2024
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. 11:e75-e85. 2024
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. 10:e684-e689. 2023
Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial. 9:e848-e856. 2022
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. 8:e633-e651. 2021
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study. 8:e363-e375. 2021
Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. 7:e772-e781. 2020
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. 7:e16-e26. 2020
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. 6:e831-e859. 2019
Have clinical trials in HIV finally matured?. 6:e561-e563. 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. 5:e211-e220. 2018
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. 4:e486-e494. 2017
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. 4:e433-e441. 2017
Household survey of HIV incidence in Rwanda: a national observational cohort study. 4:e457-e464. 2017
Preconception ART and preterm birth: real effect or selection bias? – Authors' reply. 4:e150-e151. 2017
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. 4:e31-e40. 2017
Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. 4:e21-e30. 2017
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. 3:e510-e520. 2016
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. 3:e361-e387. 2016
Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. 2:e438-e444. 2015
Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study. 2:e376-e384. 2015
Group support psychotherapy for depression treatment in people with HIV/AIDS in northern Uganda: a single-centre randomised controlled trial. 2:e190-e199. 2015
HIV care continuum in Rwanda: a cross-sectional analysis of the national programme. 2:e208-e215. 2015
Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. 1:e104-e111. 2014
Churning in and out of HIV care. 1:e58-e59. 2014

has subject area

11 Medical and Health Sciences (FoR)